On sweet undeniable feeling of power of international intellectual feudalism, bias, discrimination, censoring and theft
Heart, Vessels and Transplantation
The Heart, Vessels and Transplantation applies editorial, publishing and ethics policies in compliance with international standards set by ICMJE, NLM, CSE, WMA, WAME, EASE and COPE. It is a double-blind peer-reviewed international journal published in English language on cardiovascular surgery and transplantation, cardiovascular and internal diseases and all relevant disciplines.
Editors and owners/ publishers of the journal exercise principle of editorial freedom and independence. Editors` decisions are not affected by influence of governments, institutions, organizations, owners/publishers, sponsors and commercial advertisement providers or medical industry; authors race, gender, sexual orientation, political choices, citizenship, ethnic origin or instutional affiliation. The decisions are made solely based on importance, originality, validity, quality and relevance of submitted manuscripts for consideration for publication to the scope of the journal. The Editor-in-Chief has full authority and responsibility over content of the journal and its publication.
Role of reviewers
Reviewers are responsible to decline to review manuscript in presence of any type of conflict of interest: awareness of the submitted research/case report, authors or their institutions; as well as not to use confidential data presented in manuscript in any current or future their own projects and publications. The journal provides the standard reviewer form to be filled by reviewers, including the recommendations for authors and report for editors.
Articles submitted to the journal undergo unbiased double-blind (authors`, editors`, reviewers` names or their institutions, cities and countries of origin are not disclosed in articles, all authors, editors, reviewers participating in peer-review process are blinded) review by editors and external international reviewers (usually 2, but in case of disparate opinions 3rd reviewer is invited) experts on the topic of the manuscripts and authors of published manuscripts in international indexed journals relevant to the topic of the submitted for consideration manuscript. After receipt of submitted article, Editor-in-Chief sends article for initial review to deputy/section editors: cardiovascular surgery and transplantation; cardiology and internal medicine; electrophysiology, arrhythmias, interventional cardiology; cardiovascular imaging; and deputy/associate editors also evaluate articles on relevant disciplines/public health policies/education according to their additional areas of expertise. Section editors return article to editor within 1 week with recommendation and suggested reviewers for the article. The reviewers are informed on the principles of unbiased approach, confidentiality of manuscripts sent for review, timeliness of fulfilling reviewer assignment and quality of report. Reviewers are responsible to disclose and decline to review manuscript in presence of any type of conflict of interest: awareness of the submitted research/case report and authors or their institutions as well not to use confidential data presented in manuscript and any current of future their own projects and publications. The journal provides the standard reviewer form to be filled by reviewers, including the recommendations for authors and report for editors. Reviewers of the manuscripts are kept informed on co-reviewers reports in blind manner and final editor`s decision on manuscript. The average duration of article peer-review evaluation by reviewers – 2 weeks. Research articles and brief reports, meta-analyses and systematic reviews undergo evaluation by statistics editor of the journal. After receipt of editors`, external independent reviewers` and statistics editor`s recommendation, Editor-in-Chief makes decision based on the section editors` advice and reviewers’ reports: accept for publication, accept with minor revision, major revision with re-evaluation and reject. In cases of decisions, accept with minor revision or major revision, authors are required to submit the revised according to recommendations of editors and reviewers manuscript, highlighting changes in the articles, list of responses to comments and list of changes and letter to the editor accompanying revised manuscript within 3 weeks of receiving decision letter.
Editor-in-Chief of the journal carries responsibility for the content of the journal and has right to reject article at any step of evaluation after submission and peer-review in presence of any type of scientific or ethical misconduct. We use Crosscheck/Ithenticate software for similarity check, to prevent any ethical misconduct - plagiarism, etc.
The articles might also be rejected after ``in-house`` review by Editor-in-Chief and editors on priority basis or when submitted work is out of scope of the journal, the work is returned to authors with recommendation of submission to other journals.
Editors of the journal do not exercise policy to reject manuscripts with negative results of the study or inconclusive results, as both types of research with well-explained rationale and design might contribute to current scientific evidence and may be used in systematic reviews and meta-analyses.
Adherence of editorial policies to standards of international publications: ethics and authorship policies are fully endorsed with ICMJE, NLM, CSE, WAME, WMA, COPE rules; presentation of scientific research and case reports are endorsed with guidelines on presentation of research, systematic reviews/meta-analyses, case reports (CONSORT, STROBE, STARD, PRISMA, ARRIVE, SAMPL, CARE, Equator Network, NLM and Heart Group recommendations); editors responsibilities regarding use of drugs and medical tools are presented in detail in the Instructions for Authors and Aims and Scope of journal.
In case of typographical errors the erratum is published in the next issues. For dublicate publishing and other ethical issues (fabrication, plagiarism) with manucsript the retraction of articles is applied according to the rules set by NLM and COPE guidelines.
Scientific misconduct: data fabrication and falsification, plagiarism, manipulation of images.
Scientific miconduct in research includes data fabrication; data falsification including manipulation of images; plagiarism and purposeful failure to disclose relationships and activities. Whenever scientific misconduct is suspected, Editor-in-Chief and Editors of the journal will initiate the procedures described by Committee of Publication Ethics - https://publicationethics.org/misconduct. Editors may ask the authors explanations, contact their institutions and funding organizations, as well as publish letters of concern.
Registration of clinical trials
Heart, Vessels and Transplantation endorses ICMJE policy on registration of clinical trials (http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html).
Clinical trials should be registered at ICMJE recognized registration platforms: primary register of the WHO International Clinical Trials Registry Platform (ICTRP -
https://www.who.int/ictrp/network/primary/en/) that includes the minimum acceptable 24-item trial registration dataset (https://www.who.int/ictrp/network/trds/en/)
or in www.ClinicalTrials.gov (https://prsinfo.clinicaltrials.gov/trainTrainer/WHO-ICMJE-ClinTrialsgov-Cross-Ref.pdf), which is a data provider to the WHO ICTRP.
The International Committee of Medical Journal Editors (ICMJE) and, therefore, Heart, Vessels and Transplantation as a member of ICMJE requires researchers/authors to submit a data-sharing statement (2018) and register a data-sharing plan when registering a trial (2019).
Data sharing statements must indicate the following: whether individual deidentified participant data (including data dictionaries) will be shared; what data in particular will be shared; whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.); when the data will become available and for how long; by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism).
For more information how to prepare a statement please visit:
Prepared by Gulmira Kudaiberdieva - Editor-in-Chief of the Heart, Vessels and Transplantation